Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension.

Mergia E, Stegbauer J.

Curr Hypertens Rep. 2016 Apr;18(5):39. doi: 10.1007/s11906-016-0646-5. Review.

2.

Nitric oxide generating/releasing materials.

Liang H, Nacharaju P, Friedman A, Friedman JM.

Future Sci OA. 2015;1(1). doi: 10.4155/fso.15.54.

3.

Cyclic nucleotide phosphodiesterase 1 and vascular aging.

Yan C.

Clin Sci (Lond). 2015 Dec;129(12):1077-81. doi: 10.1042/CS20150605. Epub 2015 Sep 15.

4.

Organic Nitrate Therapy, Nitrate Tolerance, and Nitrate-Induced Endothelial Dysfunction: Emphasis on Redox Biology and Oxidative Stress.

Daiber A, Münzel T.

Antioxid Redox Signal. 2015 Oct 10;23(11):899-942. doi: 10.1089/ars.2015.6376. Epub 2015 Sep 24.

5.

Phosphodiesterase 5 attenuates the vasodilatory response in renovascular hypertension.

Stegbauer J, Friedrich S, Potthoff SA, Broekmans K, Cortese-Krott MM, Quack I, Rump LC, Koesling D, Mergia E.

PLoS One. 2013 Nov 15;8(11):e80674. doi: 10.1371/journal.pone.0080674. eCollection 2013.

6.

Vinpocetine attenuates lipid accumulation and atherosclerosis formation.

Cai Y, Li JD, Yan C.

Biochem Biophys Res Commun. 2013 May 10;434(3):439-43. doi: 10.1016/j.bbrc.2013.03.092. Epub 2013 Apr 10.

7.

Vinpocetine suppresses pathological vascular remodeling by inhibiting vascular smooth muscle cell proliferation and migration.

Cai Y, Knight WE, Guo S, Li JD, Knight PA, Yan C.

J Pharmacol Exp Ther. 2012 Nov;343(2):479-88. doi: 10.1124/jpet.112.195446. Epub 2012 Aug 22.

8.

Nitric oxide synthases in heart failure.

Carnicer R, Crabtree MJ, Sivakumaran V, Casadei B, Kass DA.

Antioxid Redox Signal. 2013 Mar 20;18(9):1078-99. doi: 10.1089/ars.2012.4824. Epub 2012 Sep 20. Review.

9.

Nitric oxide nanoparticles: pre-clinical utility as a therapeutic for intramuscular abscesses.

Schairer D, Martinez LR, Blecher K, Chouake J, Nacharaju P, Gialanella P, Friedman JM, Nosanchuk JD, Friedman A.

Virulence. 2012 Jan-Feb;3(1):62-7. doi: 10.4161/viru.3.1.18816. Epub 2012 Jan 1.

10.

Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart.

Miller CL, Cai Y, Oikawa M, Thomas T, Dostmann WR, Zaccolo M, Fujiwara K, Yan C.

Basic Res Cardiol. 2011 Nov;106(6):1023-39. doi: 10.1007/s00395-011-0228-2. Epub 2011 Oct 20.

11.

PDE1 isozymes, key regulators of pathological vascular remodeling.

Chan S, Yan C.

Curr Opin Pharmacol. 2011 Dec;11(6):720-4. doi: 10.1016/j.coph.2011.09.002. Epub 2011 Sep 29. Review.

12.
13.

Regulation of endothelial barrier function by cyclic nucleotides: the role of phosphodiesterases.

Surapisitchat J, Beavo JA.

Handb Exp Pharmacol. 2011;(204):193-210. doi: 10.1007/978-3-642-17969-3_8. Review.

14.

Decreased cGMP level contributes to increased contraction in arteries from hypertensive rats: role of phosphodiesterase 1.

Giachini FR, Lima VV, Carneiro FS, Tostes RC, Webb RC.

Hypertension. 2011 Mar;57(3):655-63. doi: 10.1161/HYPERTENSIONAHA.110.164327. Epub 2011 Jan 31.

15.

Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II.

Mokni W, Keravis T, Etienne-Selloum N, Walter A, Kane MO, Schini-Kerth VB, Lugnier C.

PLoS One. 2010 Dec 3;5(12):e14227. doi: 10.1371/journal.pone.0014227.

16.
17.

Reversal of hemoglobin-induced vasoconstriction with sustained release of nitric oxide.

Cabrales P, Han G, Nacharaju P, Friedman AJ, Friedman JM.

Am J Physiol Heart Circ Physiol. 2011 Jan;300(1):H49-56. doi: 10.1152/ajpheart.00665.2010. Epub 2010 Nov 5.

18.

cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Francis SH, Busch JL, Corbin JD, Sibley D.

Pharmacol Rev. 2010 Sep;62(3):525-63. doi: 10.1124/pr.110.002907. Review.

19.

Increased degradation of MYPT1 contributes to the development of tolerance to nitric oxide in porcine pulmonary artery.

Ma H, He Q, Dou D, Zheng X, Ying L, Wu Y, Raj JU, Gao Y.

Am J Physiol Lung Cell Mol Physiol. 2010 Jul;299(1):L117-23. doi: 10.1152/ajplung.00340.2009. Epub 2010 Apr 23.

20.

PDEs1-5 activity and expression in tissues of cirrhotic rats reveal a role for aortic PDE3 in NO desensitization.

Tahseldar-Roumieh R, Keravis T, Maarouf S, Justiniano H, Sabra R, Lugnier C.

Int J Exp Pathol. 2009 Dec;90(6):605-14. doi: 10.1111/j.1365-2613.2009.00678.x. Epub 2009 Sep 15.

Items per page

Supplemental Content

Write to the Help Desk